Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens

AIDS Research and Human Retroviruses

Volumn 31, Issue 1, 2015, Pages 71-77

  Baroncelli, Silvia ^a   Pirillo, Maria Franca ^a   Galluzzo, Clementina Maria ^a   Antoni, Anna Degli ^b   Ladisa, Nicoletta ^c   Francisci, Daniela ^d   D'ettorre, Gabriella ^e   Segala, Daniela ^f   Vivarelli, Angela ^g   Sozio, Federica ^h   Cirioni, Oscar ⁱ   Weimer, Liliana Elena ^a   Fragola, Vincenzo ^a   Parruti, Giustino ^h   Floridia, Marco ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^g Ospedale Civile   (Italy)

^h Pescara General Hospital   (Italy)

ⁱ UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RALTEGRAVIR; VIRUS RNA; 2 PYRROLIDONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS DNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG USE; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FAILURE; MALE; MEDICAL HISTORY; MIXED INFECTION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS ENTRY; VIRUS LOAD; ACQUIRED IMMUNODEFICIENCY SYNDROME; BLOOD; DRUG EFFECTS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV SEROPOSITIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; VIREMIA; VIROLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COINFECTION; DNA, VIRAL; FEMALE; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; MIDDLE AGED; PYRROLIDINONES; RALTEGRAVIR POTASSIUM; RNA, VIRAL; VIRAL LOAD; VIREMIA;

EID: 84937130791     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2014.0060     Document Type: Article

References (49)

1. Havlir DV, Koelsch KK, Strain MC, et al.: Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. J Infect Dis 2005;19:1164-1168
2. Palmer S, Maldarelli F, Wiegand A, et al.: Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 2008;105: 3879-3884
3. Dornadula G, Zhang H, VanUitert B, et al.: Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999;282:1627-1632
4. Pinzone MR, Di Rosa M, Cacopardo B, et al.: HIV RNA suppression and immune restoration: Can we do better?. Clin Dev Immunol 2012;2012:515962
5. Palmer S: Advances in detection and monitoring of plasma viremia in HIV-infected individuals receiving antiretroviral therapy. Curr Opin HIV AIDS 2013;8:87-92
6. Finzi D, Blankson J, Siliciano JD, et al.: Latent infection of CD4 + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999;5:512-517
7. Siliciano JD, Kajdas J, Finzi D, et al.: Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4 + T cells. Nat Med 2003;9:727-728
8. Grossman Z, Polis M, Feinberg MB, et al.: Ongoing HIV dissemination during HAART. Nat Med 1999;5:1099-1104
9. Maldarelli F, Palmer S, King MS, et al.: ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 2007;3:e46
10. Günthard HF, Frost SD, Leigh-Brown AJ, et al.: Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol 1999;73:9404-9412
11. Sharkey ME, Teo I, Greenough T, et al.: Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med 2000;6:76-81
12. Petitjean G, Al Tabaa Y, Tuaillon E, et al.: Unintegrated HIV-1 provides an inducible and functional reservoir in untreated and highly active antiretroviral therapy-treated patients. Retrovirology 2007;4:60
13. Zheng L, Bosch RJ, Chan ES, et al.: Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy. Antivir Ther 2013;18:39-43
14. Gandhi RT, Zheng L, Bosch RJ, et al.: The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: A randomized controlled trial. PLoS Med 2010;7(8):e1000321
15. Hatano H, Hayes TL, Dahl V, et al.: A randomized, controlled trial of raltegravir intensification in antiretroviraltreated, HIV-infected patients with a suboptimal CD4 + T cell response. J Infect Dis 2011;203:960-968
16. McMahon D, Jones J, Wiegand A, et al.: Short-course raltegravir intensification does not reduce persistent lowlevel viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 2010;50:912-919
17. Buzón MJ, Massanella M, Llibre JM, et al.: HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 2010;16:460-465
18. Dinoso JB, Kim SY, Wiegand AM, et al.: Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci USA 2009;106:9403-9408
19. Vallejo A, Gutierrez C, Hernandez-Novoa B, et al.: The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients. AIDS 2012;26:1885-1894
20. Maggiolo F, Callegaro A, Cologni G, et al.: Ultrasensitive assessment of residual low-level HIV viremia in HAARTtreated patients and risk of virological failure. J Acquir Immune Defic Syndr 2012;60:473-482
21. Corbeau P and Reynes J: Immune reconstitution under antiretroviral therapy: The new challenge in HIV-1 infection. Blood 2011;117:5582-5590
22. Cohen C: Low-level viremia in HIV-1 infection: Consequences and implications for switching to a new regimen. HIV Clin Trials 2009;10:116-124
23. Bucciardini R, DEttorre G, Baroncelli S, et al.: Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors. Int J STD AIDS 2012;23:459-463
24. Stanford University HIV Drug Resistance Database, Stanford University: http://hivdb.stanford.edu/. Accessed January 5, 2014
25. Rhee SY, Fessel WJ, Liu TF, et al.: Predictive value of HIV-1 genotypic resistance test interpretation algorithms. J Infect Dis 2009;200:453-463
26. Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo .nih.gov/ContentFiles/Adultand AdolescentGL.pdf. Accessed January 10, 2014
27. Di Mascio M, Dornadula G, Zhang H, et al.: In a subset of subjects on highly active antiretroviral therapy, human immunodeficiency virus type 1 RNA in plasma decays from 50 to 5 copies per milliliter, with a half-life of 6 months J Virol 2003 77 2271-2275
28. Ramratnam B, Ribeiro R, He T, et al. Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication J Acquir Immune Defic Syndr 2004 35 33-37
29. Llibre JM, Buzón MJ, Massanella M, et al.: Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: A randomized 48-week study. Antivir Ther 2012;17:355-364
30. Li JZ, Gallien S, Ribaudo H, et al.: Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia. AIDS 2014;28:181-186
31. Pulido F, Hill A, van Delft Y, et al.: Impact of hepatitis C co-infection on response to antiretroviral treatment. AIDS Rev 2012;14:124-131
32. Hua L, Andersen JW, Daar ES, et al.: Hepatitis C virus/ HIV coinfection and responses to initial antiretroviral treatment. AIDS 2013;27:2725-2734
33. Motta D, Brianese N, Focà E, et al.: Virological effectiveness and CD4 + T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: Focus on HCV and anchor class received. AIDS Res Ther 2012;1:9-18
34. Chun TW, Justement JS, Moir S, et al.: Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: Implications for eradication of virus. J Infect Dis 2007;195:1762-1764
35. Strain MC, Little SJ, Daar ES, et al.: Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1. J Infect Dis 2005;191:1410-1418
36. Chun TW, Murray D, Justement JS, et al.: Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis 2011;204:135-138
37. Hocqueloux L, Prazuck T, Avettand-Fenoel V, et al.: Longterm immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 2010;24:1598-1601
38. Hocqueloux L, Avettand-Fènoël V, Jacquot S, et al.: Longterm antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. J Antimicrob Chemother 2013;68: 1169-1178
39. Sáez-Cirión A, Bacchus C, Hocqueloux L, et al.: Posttreatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy. ANRS VISCONTI Study. PLoS Pathog 2013;9:e1003211.
40. Marks G, Gardner LI, Craw J, et al.: Entry and retention in medical care among HIV-diagnosed persons: A metaanalysis. AIDS 2010;24:2665-2678
41. Jennessa SM, Myersbc JE, Neaigusd A, et al.: Delayed entry into HIV medical care after HIV diagnosis: Risk factors and research methods. AIDS Care 2012; 24(10): 1240-1248
42. Siegfried N, Uthman OA, and Rutherford GW: Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults. Cochrane Database Syst Rev 2010;3:CD008272
43. Kretzschmar ME, van der Loeff MF, Birrell PJ, et al.: Prospects of elimination of HIV with test-and-treat strategy. Proc Natl Acad Sci USA 2013;110:15538-15543
44. Widdrington J, Payne B, Medhi M, et al.: The significance of very low-level viraemia detected by sensitive viral load assays in HIV infected patients on HAART. J Infect 2011; 62:87-92
45. Baroncelli S. Galluzzo C, Pirillo MF, et al.: Microbial translocation is associated with residual viral replication in HAART treated HIV + subjects with 50 copies/ml HIV-1 RNA. J Clin Virol 2009 46 367-370
46. dEttorre G, Paiardini M, Zaffiri L, et al.: HIV persistence in the gut mucosa of HIV-infected subjects undergoing antiretroviral therapy correlates with immune activation and increased levels of LPS. Curr HIV Res 2011;9:148-153
47. Gianotti N, Galli L, Racca S, et al.: Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. J Antimicrob Chemother 2012;67:213-217
48. Eastburn A, Scherzer R, Zolopa AR, et al.: Association of low level viremia with inflammation and mortality in HIVinfected adults. PLoS One 2011;6:e26320
49. Charpentier C, Landman R, Laouénan C, et al.: Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: Associated factors and virological outcome. J Antimicrob Chemother 2012;67:2231-2235